$THRX News
Last published 2y ago
- 2y agoTHRXTheseus Pharmaceuticals Announces Closing of Tender OfferPR NewswireTheseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives...
- 2y agoTHRXConcentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus PharmaceuticalsBusiness WireAs previously announced on December 22, 2023, Concentra Biosciences, LLC ("Parent") and its wholly owned subsidiary, Concentra Merger Sub II, Inc. ("Purchaser"), entered into a merger agreement (the "Merger Agreement")
- 2y agoTHRXTheseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value RightPR NewswireTheseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives...
- 2y agoTHRXTheseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLCPR NewswireOn November 22, 2023, the board of directors (the Board) of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) received an...
- 3y agoTHRXTheseus Pharmaceuticals Announces Process to Explore Strategic AlternativesPR NewswireTheseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of...
- 3y agoTHRXTheseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare ConferencePR NewswireTheseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of...
- 3y agoTHRXTheseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial ResultsPR NewswireIND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023 Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024 Nomination of highly selective pan-variant KIT inhibitor
- 3y agoTHRXTheseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GISTPR Newswire-- Decision follows two dose-limiting toxicities related to hand-foot skin reaction observed in Cohort 7 (27 mg) -- -- Company prioritizing THE-349, a potentially best-in-class fourth-generation EGFR inhibitor for EGFR
- 3y agoTHRXTheseus Pharmaceuticals to Participate in the Jefferies Healthcare ConferencePR NewswireCAMBRIDGE, Mass., May 31, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the
- 3y agoTHRXTheseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GISTPR Newswire-- THE-630 demonstrates encouraging safety profile through Cohort 6 (18 mg), supportive of continued dose escalation -- -- Dose-dependent reductions observed in ctDNA KIT-mutant allele fractions for both major classes
- 3y agoTHRXTheseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial ResultsPR Newswire-- THE-630 initial dose escalation data to be presented at investor event on May 25, 2023, with additional dose escalation data expected in Q4 2023 -- -- IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4
- 3y agoTHRXTheseus Pharmaceuticals Initial Dose Escalation Results from Ongoing Phase 1/2 Trial of THE-630 Accepted for Online Publication at 2023 ASCO Annual MeetingPR Newswire-- Company to host virtual investor event to review updated data on May 25, 2023 at 5:30pm ET -- CAMBRIDGE, Mass., April 26, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company), a
- 3y agoTHRXTheseus Pharmaceuticals to Participate in Upcoming Investor ConferencesPR NewswireCAMBRIDGE, Mass., April 11, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the
- 3y agoTHRXTheseus Pharmaceuticals to Participate in the Cantor Future of Oncology Virtual SymposiumPR NewswireCAMBRIDGE, Mass., March 28, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the
- 3y agoTHRXTheseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial ResultsPR NewswireTHE-630 phase 1 preliminary dose-escalation data anticipated in Q2 2023; additional data including dose levels projected preclinically to provide pan-variant KIT coverage planned for Q4 2023 IND submission expected in Q4
- 3y agoTHRXTheseus Pharmaceuticals to Participate in the SVB Securities Global Biopharma ConferencePR NewswireCAMBRIDGE, Mass., Feb. 7, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the
- 3y agoTHRXTheseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development ProgramPR NewswireProgressing Phase 1/2 clinical trial of THE-630 in advanced GIST; preliminary dose-escalation data anticipated in Q2 2023 with additional data expected in Q4 2023 IND submission for 4G EGFR inhibitor THE-349 expected in
- 4y agoTHRXTheseus Pharmaceuticals Presents Preclinical Data Characterizing THE-349, its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR SymposiumPR NewswirePotent single-molecule inhibition of all major classes of EGFR activating and resistance mutations, including C797X and T790M, with a high degree of kinome and wild-type EGFR selectivity Deep and durable tumor
- 4y agoTHRXTheseus Pharmaceuticals Appoints Steven Stein, M.D. to Board of DirectorsPR NewswireCAMBRIDGE, Mass., Oct. 19, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through
- 4y agoTHRXTheseus Pharmaceuticals Nominates THE-349, a Fourth-Generation EGFR Inhibitor Development Candidate in Non-Small Cell Lung CancerPR NewswireTHE-349 is a fourth-generation, potent and selective, small molecule designed to inhibit all major classes of EGFR activating and resistance mutations Preclinical data to be presented at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Canc
- 4y agoTHRXTheseus Pharmaceuticals to Participate at Upcoming September Investor ConferencesPR NewswireCAMBRIDGE, Mass., Sept. 6, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and com
- 4y agoTHRXTheseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Second Quarter 2022 Financial ResultsPR NewswireTHE-630 Phase 1/2 clinical trial enrolling patients; initial data expected in Q2 2023 Nomination of development candidate for fourth-generation epidermal growth factor receptor (EGFR) inhibitor program expected in Q3 2022; IND expected in 2023 $228.6
- 4y agoTHRXTheseus Pharmaceuticals to Participate Virtually in Wedbush PacGrow Healthcare ConferencePR NewswireCAMBRIDGE, Mass., Aug. 3, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and comm
- 4y agoTHRXTheseus Pharmaceuticals to Participate in Upcoming Investor ConferencesPR NewswireCAMBRIDGE, Mass., May 19, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and comm
- 4y agoTHRXTheseus Pharmaceuticals Appoints Don Hayden to Board of DirectorsPR NewswireCAMBRIDGE, Mass., May 18, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and comme
- 4y agoTHRXTheseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2022 Financial ResultsPR NewswireTHE-630 Phase 1/2 clinical trial actively enrolling patients with advanced gastrointestinal stromal tumors (GIST); initial data expected in 1H 2023 On track to nominate development candidate for fourth-generation epidermal growth factor receptor (EGFR)
- 4y agoTHRXTheseus Pharmaceuticals Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual MeetingPR NewswirePoster presentation details lead compounds demonstrating activity against EGFR variants that are resistant to all approved EGFR inhibitors Nomination of development candidate expected in Q3 2022; IND expected in 2023 CAMBRIDGE, Mass., April 8, 2022 /
- 4y agoTHRXTheseus Pharmaceuticals to Participate Virtually in Needham Healthcare ConferencePR NewswireCAMBRIDGE, Mass., April 5, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercializatio
- 4y agoTHRXTheseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial ResultsPR NewswireCAMBRIDGE, Mass., March 10, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and co
- 4y agoTHRXTheseus Pharmaceuticals to Present Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual MeetingPR NewswireCAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and com
- 4y agoTHRXTheseus Pharmaceuticals to Participate Virtually in SVB Leerink Global Healthcare ConferencePR NewswireCAMBRIDGE, Mass., Feb. 9, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization
- 4y agoTHRXTheseus Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for THE-630 for the Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)PR NewswireCAMBRIDGE, Mass., Feb. 2, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (Theseus) (NASDAQ:THRX), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of
- 4y agoTHRXTheseus Pharmaceuticals Announces First Patient Treated with THE-630 in Phase 1/2 Study in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)PR NewswireCAMBRIDGE, Mass., Jan. 10, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (Theseus) (NASDAQ:THRX), a clinical stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization
- 4y agoADGIICVXIKNAIMGO+5Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science CompaniesPR NewswireBOSTON, Dec. 17, 2021 /PRNewswire/ -- Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced it has closed its seventh and largest fund with $650 million in limited part
- 4y agoTHRXTheseus Pharmaceuticals Announces Business and Program Highlights and Reports Third Quarter 2021 Financial ResultsPR NewswireCAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targete
- 5y agoTHRXTheseus Pharmaceuticals to Participate Virtually in Jefferies London Healthcare ConferencePR NewswireCAMBRIDGE, Mass., Nov. 10, 2021 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) ("Theseus"), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transforma
- 5y agoTHRXTheseus Pharmaceuticals Announces Pricing of Initial Public OfferingPR NewswireCAMBRIDGE, Mass., Oct. 6, 2021 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. ("Theseus"), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted t
- 13y agoTHRXELNTheravance and Elan Enter Into a $1.0 Billion Royalty Participation AgreementBusiness WireSOUTH SAN FRANCISCO, Calif. & DUBLIN--(BUSINESS WIRE)--Theravance, Inc. (NASDAQ: THRX) and Elan Corporation, plc (NYSE: ELN) today announced that they have entered into a royalty participation agreement wherein Elan will purchase a participation interest in potential future royalty payments related to four respiratory programs partnered with GlaxoSmithKline plc (GSK): RELVAR™ ELLIPTA™/BREO™ ELLIPT ...
- 13y agoTHRXCLINIGEN UK Regulatory Announcement: Clinigen Group and Theravance Entered into Exclusive Commercialization Agreement in the EU for Antibacterial VIBATIV®Business WireBURTON-ON-TRENT, England & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--